Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODULAATE Study: Alpha-1 antitrypsin to prevent graft-versus-host disease after hematopoietic cell transplant
2018-000329-29Phase 2Unknown
- Sponsor
- CSL Behring
- Start
- Sep 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Acute Graft-Versus-Host Disease (aGvHD) comparing Alpha-1 antitrypsin with Placebo (2 arms). Primary endpoint: Grade II-IV acute graft-versus-host disease-free survival (aGFS). Status: unknown.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on 2018-000329-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000329-29.